Opinion
Video
Similarities and Differences Among PSMA-PET Tracers
Author(s):
A nuclear radiologist provides an overview of the gallium- and fluorine-based PSMA-PET tracer options, highlighting factors that influence tracer selection.
Video Player is loading.
Video content above is prompted by the following questions:
- There are currently gallium- and fluorine-based PSMA-PET tracer options that are FDA approved. Can you review some of similarities and differences between the gallium and fluorine imaging tracer options identified above in terms of image quality and resolution? And accuracy and false positives?
- Gallium and fluorine tracers also have different half-lives. What does this mean in real-world practice in terms of patient scheduling and preparing for imaging? Can you provide any real-world examples of when one tracer may be preferential over another?
- There are two available F18 tracers available: 18F-Piflufolastat and 18F-Flotufolastat. What are some of the key differences between these? Can you share any examples of differences you’ve seen between these two tracers when used in real-world practice?
Related Videos
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Dr Louise Kostos discusses combination therapies in mHSPC
Neeraj Agarwal, MD, on the design of the TALAPRO-2 trial
Related Content
